TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31936727
Drug: CrM group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrM group (0.04 g/kg/day of CrM)
Study: 31936727
Drug: HMB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB group (3 g/day of HMB)
Study: 29531290
Drug: Bedtime ingestion
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime ingestion of hypertension medications (n=1037)
Study: 29531290
Drug: Morning ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning ingestion of hypertension medications (n=1041)
Study: 27365521
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral care (teeth surface cleaning, scaling, and tongue cleaning weekly for 8 weeks)
Study: 25040447
Drug: Financial education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial education and support programme plus nicotine replacement therapy (NRT) for 8 weeks
Study: 25040447
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) for 8 weeks plus Quitline support
Study: 21197854
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (5.0 mg caffeine/kg bodyweight)
Study: 16758942
Drug: Fraxiparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparin (low molecular-weight heparin) administered before surgery
Study: 16758942
Drug: Fraxiparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparin (low molecular-weight heparin) administered after surgery
Study: 16758942
Drug: Preoperative preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preventive treatment with Fraxiparin
Study: 12676037
Drug: Usual postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual postoperative care plus massage therapy
Study: 12676037
Drug: Usual postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual postoperative care plus vibration therapy
Study: 7967328
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (165 mg once daily)
Study: 7967328
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of heparin (1,000 units per hour)
Study: 3981166
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg dose of metoprolol
Study: 27018419
Drug: Diphenhydramine citrate
Normalized name: Diphenhydramine Citrate
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine citrate 76 mg
Study: 22305276
Drug: Curcuminoids (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (varied doses)
Study: 17888192
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine + 10 mL saline epidurally (Group B)
Study: 17888192
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine + 10 mL saline epidurally (Group D)
Study: 15987848
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ascorbic Acid (AA) twice daily for 6 days
Study: 12622584
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (INO) 80 ppm with 21% final concentration of inspired oxygen (n=10)
Study: 10582983
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg po daily) for 6 weeks
Study: 8915035
Drug: Donepezil (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (1, 3, or 5 mg)
Study: 6188770
Drug: Local terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local terbutaline (nontoxic doses)
Study: 30267032
Drug: ISA 101
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA 101 vaccine (100 μg/peptide) given subcutaneously on days 1, 22, and 50; Nivolumab (3 mg/kg) given intravenously every 2 weeks starting day 8 for up to 1 year
Study: 29294223
Drug: Pre-admission use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-admission use of antiplatelet drugs
Study: 26724834
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) during induction and/or maintenance therapy
Study: 24316679
Drug: NeReBot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeReBot therapy (robotic training 35% of exercise time) + standard therapy (65% of exercise time)
Study: 24316679
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for the upper limb (control group)
Study: 22584796
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenously four times daily) and fludrocortisone (50 μg orally once daily)
Study: 11771665
Drug: Letrozole (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (aromatase inhibitor) for 6 months
Study: 8131700
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once a day for 5 days
Study: 8131700
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omeprazole and enprostil
Study: 2563786
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake group (53 subjects; diet containing less than 80 mmol sodium/day plus 8 placebo tablets daily)
Study: 2563786
Drug: Normal sodium
Normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal sodium intake group (55 subjects; same dietary sodium plus 8 slow-release sodium chloride [10 mmol] tablets daily)
Study: 24280617
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of botulinum toxin A (BoNT/A)
Study: 24280617
Drug: Microneedle fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle fractional radiofrequency (MFR) therapy
Study: 24280617
Drug: BoNT/A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injection side
Study: 21680997
Drug: Irbesartan/HCTZ (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ (150 mg/12.5 mg titrated to 300 mg/25 mg)
Study: 8597317
Drug: lovastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin, 80 mg/d
Study: 1822427
Drug: Full inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full inpatient treatment
Study: 31595295
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish consumption (∼300 g/wk)
Study: 15766818
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 to 4 mg/day)
Study: 10557167
Drug: Fluoride drops
Normalized name: SODIUM FLUORIDE 2.5 mg in 1 mL ORAL LIQUID [FLUORIDE DROPS]
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride drops (0.25 mg for 2-3 year-olds, 0.5 mg for older children) taken daily for 3 years
Study: 8575054
Drug: Alcuronium (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium (0.3 mg/kg)
Study: 28213908
Drug: Lacosamide (LCM)
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide (LCM) 400 mg at a rate of 60 mg/kg/min
Study: 16386537
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg) and vitamin B12 (500 mg) daily for 3 months
Study: 10461765
Drug: Lactate capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate capsule (Control)
Study: 7609265
Drug: Monoclonal antiendotoxin
Normalized name: Monoclonal antiendotoxin antibody XMMEn-0e5
DrugBank: Edobacomab (DB17779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antiendotoxin antibody
Study: 2507435
Drug: Metoclopramide (MCP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (MCP, 10 mg orally 3 times daily for 7 days)
Study: 324556
Drug: Cephaloridine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephaloridine (1 g in 2 ml of water)
Study: 324556
Drug: Ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (1 g in 2 ml of water)
Study: 31332655
Drug: Lung ultrasound-guided
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound-guided therapy (semi-quantitative evaluation of B lines and the presence of pleural effusion)
Study: 31332655
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (clinical assessment of congestion)
Study: 28395844
Drug: Co-trimoxazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (100 mg/20 mg once daily until age 6 months and 200 mg/40 mg once daily thereafter)
Study: 23075046
Drug: Hyperbaric articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric articaine 72 mg with fentanyl 10 μg (Group A + F)
Study: 23075046
Drug: Hyperbaric articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric articaine 72 mg without fentanyl (Group A)
Study: 19317864
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine infused at 8.4 ml/h (low concentration group, n=35)
Study: 19317864
Drug: 0.75% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% levobupivacaine infused at 1.4 ml/h (high concentration group, n=35)
Study: 17369566
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenously on day 1 only)
Study: 15479682
Drug: Probiotic Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Escherichia coli Nissle 1917, 200 mg once daily (n = 162)
Study: 15479682
Drug: Mesalazine, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine, 500 mg three times daily (n = 165)
Study: 9390616
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% in new formulation
Study: 9390616
Drug: Standard propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard propofol formulation
Study: 29382251
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment for nodding syndrome
Study: 26275982
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (metoprolol and carvedilol)
Study: 26275982
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (diltiazem and verapamil)
Study: 21132360
Drug: E (100
Normalized name: ETHYLCELLULOSE (100 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (100 mg/m² i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m² i.v. d1 and 8, q28 days for 4 cycles)
Study: 11317536
Drug: Live tularemia
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live tularemia vaccine
Study: 9039083
Drug: Human brain
Normalized name: Human brain natriuretic factor-32
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human brain natriuretic peptide-32 at a dose of 4 pmol/kg per minute
Study: 9039083
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose infusion (control)
Study: 8284070
Drug: Meclofenamate 50
Normalized name: meclofenamate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate 50 mg
Study: 8284070
Drug: Ibuprofen (multidose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (multidose phase)
Study: 3443139
Drug: Prazosin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (n = 40, 1.5‐12.0 mg per day)
Study: 3443139
Drug: Propranolol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (n = 30, 30‐120 mg per day)
Study: 20559708
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m²) plus Cyclophosphamide (600 mg/m²) every 3 weeks (AC)
Study: 20559708
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m²) plus Docetaxel (75 mg/m²) every 3 weeks (AD)
Study: 18481035
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg l-amphetamine
Study: 18481035
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg l-amphetamine
Study: 16162746
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (oral warfarin and low-molecular-weight heparin) plus prednisolone
Study: 16162746
Drug: Prednisolone alone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone alone (non-anticoagulant group)
Study: 16162746
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (during acute exacerbation)
Study: 7778637
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (25 micrograms every 3 hours, max 8 doses)
Study: 7778637
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone (0.5 mg every 6 hours, max 3 doses)
Study: 31877968
Drug: Brazil nut
Normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nut oil (BNO), 10 mL daily for 30 days
Study: 31877968
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (SO), 10 mL daily for 30 days
Study: 28573246
Drug: Body Awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Awareness Therapy (BAT)
Study: 26152421
Drug: Toltrazuril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toltrazuril (15 mg/kg)
Study: 23703422
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR (50, 75, or 100 mg)
Study: 23703422
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR (5, 10, or 15 mg)
Study: 15282383
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg natural vitamin E for 6 weeks
Study: 11317052
Drug: Postnatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal steroids
Study: 7824863
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g lactulose ingestion in methane producers
Study: 7824863
Drug: 10 g,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g, 20 g, and 30 g lactulose ingestion
Study: 7824863
Drug: Methane and
Normalized name: Dichloromonofluoromethane and trichlorofluoromethane only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methane and hydrogen excretion measurements
Study: 27285345
Drug: Combined aerobic-resistance
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined aerobic-resistance exercise therapy (3 weekly sessions of 60 minutes for 12 weeks)
Study: 11284816
Drug: No neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neuromuscular blocking drugs
Study: 27694633
Drug: RSV-PreF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV-PreF vaccine with 10 µg
Study: 27694633
Drug: RSV-PreF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV-PreF vaccine with 30 µg and alum adjuvant
Study: 27694633
Drug: RSV-PreF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV-PreF vaccine with 60 µg and alum adjuvant
Study: 27694633
Drug: RSV-PreF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV-PreF vaccine with 60 µg and nonadjuvant
Study: 27694633
Drug: RSV-PreF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV-PreF vaccine (all dosages)
Study: 23165609
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (Iso: 165 mg/d)
Study: 16887418
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy with edetate calcium disodium (EDTA) for 3 months and repeated therapy to maintain BLB below 20 microg
Study: 15251637
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin (CII) therapy
Study: 24373823
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy with Na2B12H11SH (BSH)
Study: 24373823
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy with p‐dihydroxyborylphenylalanine (BPA)
Study: 17803837
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (case manager-coordinated medication support and brief psychological treatment, enhanced specialist and GP communication)
Study: 15601269
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ephedrine
Study: 15601269
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of mephentermine
Study: 12227391
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g/L intraperitoneally as loading dose, repeated on day 5 or day 8 for 2 weeks.
Study: 12227391
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g in the first PD bag and continued with 125 mg/L every exchange for 2 or 3 weeks, depending on culture results.
Study: 9708650
Drug: tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tissue plasminogen activator (t‐PA) therapy within 2 hours of acute symptom onset
Study: 9708650
Drug: tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tissue plasminogen activator (t‐PA) therapy after 2 hours
Study: 9708650
Drug: tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tissue plasminogen activator (t‐PA) therapy
Study: 2095291
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg), administered 2 hours after reading the text
Study: 2095291
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg), administered before reading the text
Study: 2095291
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered before reading the text
Study: 2095291
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered 2 hours after reading the text
Study: 668776
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 50 g suspended in water
Study: 28219430
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health system (tablet computer and pulse oximeter)
Study: 19210949
Drug: Brief cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioral therapy (CBT) delivered by mental health nurses trained over 10 days with ongoing supervision
Study: 14975603
Drug: Interferon-beta 1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta 1b treatment
Study: 9881518
Drug: Selenium enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium enriched yeast (4.8 mg containing 5 microg selenium daily via nasogastric drip during the first 14 postnatal days)
Study: 2484663
Drug: Pirbuterol 0.2
Normalized name: pirbuterol 0.2 mg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 0.2 mg
Study: 2484663
Drug: Metaproterenol 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol 1.3 mg
Study: 22293363
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 4,000 IU daily for 12 weeks
Study: 20197426
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of ICS
Study: 20197426
Drug: Adding a
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding a leukotriene-receptor antagonist to the ICS
Study: 20197426
Drug: Adding a
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding a long-acting beta-agonist to the ICS
Study: 1823147
Drug: Oral selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selenium plus copper associated with vitamin complex (tocopherol and retinol)
Study: 6860416
Drug: Once-daily tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tobramycin dosing
Study: 6860416
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of gentamicin, tobramycin, or netilmicin
Study: 6860416
Drug: Continuous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous tobramycin dosing
Study: 21131037
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg infusion every 3-4 weeks)
Study: 21131037
Drug: Clodronic acid
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronic acid (1600 mg oral daily)
Study: 17627194
Drug: Reiki touch
Normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reiki touch therapy
Study: 15760966
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (buserelin) 0.5 mg s.c.
Study: 1934552
Drug: Ear-canal magnets
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear-canal magnets treatment